Peter Szijj
@PeterSzijj
Followers
94
Following
852
Media
7
Statuses
150
Post-doctoral Researcher at Stanford University, @Stanford_ChEMH, Bertozzi group. PhD Graduate from @ismb_london and @UCLChemistry.
Stanford, CA
Joined March 2014
It has been four years since this journey started, but (this chapter at least) has come to an end! Our work on "Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer" is now online in @NatureChemistry! https://t.co/jUd5EFBswL 1/9
6
19
37
Breaking news: Thousands of researchers and their supporters, including recently fired federal workers, have gathered across the U.S. in response to layoffs and funding cuts ordered by the Trump administration.
science.org
Scientists and their supporters rallied across the country in response to layoffs and funding cuts ordered by the Trump administration
59
361
1K
The mood was defiant at many of the rallies, where chants of “Scientists will not be silenced”, “Facts over fear” and “What do we want? Peer review! When do we want it? Now!” were heard. https://t.co/Ux1g91McIV
63
322
982
I would edit this to remove the "my", but to do that, I would have to subscribe to premium. What a bind.
0
0
0
Since it is my Twitter/X "Premium's Anniversary", to celebrate this momentous occasion, follow me on BlueSky if you'd like: https://t.co/jJLcQlsZlJ
1
0
1
Excited to report that protocol for DNA-encoded, Liquid Glycan Array (LiGA) is out in @NatureProtocols. In addition to the protocol, we report how the expression level of Siglecs and cell types affect their ability to bind to LiGA. https://t.co/sdcmpVj2FA
3
12
35
🚨PhD Opportunity:🚨 Come and join us and @VijayChudasama_ at UCL Chemistry investigating new chemical methods for empowering antibody conjugates partnered with @GSK! 🧪 See https://t.co/qiPX93pOmV for more info: https://t.co/jul9fxS07u
0
18
34
#MeetTheResearcher Introducing André Shamsabadi, PhD from the Stevens Group this week. André is a Research Associate, working on design and application of novel nanoparticle-bioreceptor conjugates for ultra-sensitive biosensing. #KavliOxford
1
3
6
Excited to share our latest @NaturePortfolio @MethodsPrimers Primer of Top-down Proteomics. Here we discuss the underlying principles, recent advances, and present an outlook on the future. Beautiful PrimeView by Haley Wallen & Sam Whitham. Check it out!!👉 https://t.co/r7YugfjrLS
New this week: Top-down proteomics top-down proteomics analyses whole proteins without prior digestion. This Primer explores mass spectrometry experimental methods, sample preparation, data analysis and applications in understanding human disease. https://t.co/hWgSme5L9R
0
9
33
Congrats to all winners and my superstar friend @DSRoberts007 !
1
2
16
Very proud to share our latest collaborative paper with @BakerGroupUCL where we disclose the chemo- and regio-selective differential modification of cysteines on a native antibody; a first-in-class strategy! Led by the fantastic @yapyongyi! @UCLChemistry
https://t.co/ssC308zyk1
pubs.rsc.org
Protein modification has garnered increasing interest over the past few decades and has become an important tool in many aspects of chemical biology. In recent years, much effort has focused on...
3
11
37
@pengwuTSRI Update: This paper is now out! https://t.co/9dCyLK9DU7 Congrats @pengwuTSRI, Zhuo Yang, and team!
nature.com
Nature Biomedical Engineering - The removal of terminal sialic acid residues on glycans at the T-cell–tumour-cell interface via a sialidase fused to a bispecific T-cell engager enhances the...
0
0
2
1/7 Our work online today, showing that targeted desialylation enhances the efficacy of bispecific T-cell engager (BiTE) for treating solid tumors #glycotime
5
14
28
Huge congrats to my friend Mari!!
Excited to share that I'll be joining the Department of Chemistry and Biochemistry at the University of @NotreDame as a Huisking Foundation Assistant Professor in January 2025! My lab will develop chemical tools to retrain our immune system in cancer, autoimmunity, and more.
0
1
14
Antibody drug conjugates (ADCs) are all the rage, for good reason. They're generating stellar efficacy results in clinic, though they're not perfect. I looked through 40+ ADC companies founded after 2010 to see what each was trying to improve on and with what new approach. ⬇️
3
20
99
Glad to see our work on Genetically Encoded LYTACs (GELYTACs) in @PNASNews. Highlights include directed evolution of GELYTACs & secretion of GELYTACs by primary T-cells. Special thanks to @aliceyting @CarolynBertozzi, and collaborators @mackalllab.
pnas.org
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versio...
2
19
95
Excited to see our worked on PGL metabolic labeling published in ACS Chem Bio! Thank you to all our collaborators and my postdoctoral advisor @CarolynBertozzi
https://t.co/uIkysxMl6V
pubs.acs.org
Surface lipids on pathogenic mycobacteria modulate infection outcomes by regulating host immune responses. Phenolic glycolipid (PGL) is a host-modulating surface lipid that varies among clinical...
8
8
70
New review from Lina Petersone & I highlights recent findings on IL-21 and germinal center biology. Such an interesting cytokine! https://t.co/2dWdEak4f3
3
15
58
Our new review on the Immunology of #Type1Diabetes now out in @NatRevImmunol – really important area for understanding and maximising immunotherapies. Kevan Herold @Bruskolab Thomas Delong, Ana Luisa Perdigoto, Noah Biru @DUK_research @JDRFUK @iit_ucl
https://t.co/8VJXdTZcUw
2
28
99